In conclusion, skin side effects are common with ibrutinib treatment, but leukocytoclastic
vasculitis is a serious complication of treatment and may require ibrutinib discontinuation. In …

DISCUSSION Our case presented as a table of severe cutaneous vasculitis that
necessitated discontinuation of ibrutinib treatment. Ibrutinib inactivates BTK by covalently …

A limited literature search was conducted by an information specialist on key resources,
including MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the …

The small-molecule drug ralimetinib was developed as an inhibitor of the p38α mitogen-
activated protein kinase, and it has advanced to phase 2 clinical trials in oncology. Here, we …

Discussion Ibrutinib is a selective Bruton tyrosine kinase inhibitor used for treatment of
several lymphoproliferative disorders, including CLL, mantle cell lymphoma, marginal zone …

Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib
Page 1 CPD • A memorable patient CED Clinical and Experimental Dermatology CPD …

Currently available evidence describing second-or third-line therapies for treatment-
refractory chronic graft-versus-host disease was ineligible for this review because of the use …